In a significant move to bolster the United Kingdom’s position as a global leader in life sciences and medical technology, the British Business Bank (BBB)—the UK government’s economic development bank—has announced a €25 million ($28.6 million) investment into the EQT Health Economics 3 Fund (EQT HE3). This strategic allocation marks a deepening of the partnership between the UK public sector and one of Europe’s most prominent venture capital firms, aimed at scaling commercial-stage medical technology and digital health enterprises.
Main Facts: The Strategic Injection of Capital
The EQT HE3 fund, which officially launched in 2024, has now reached a total fund size of €216 million. The fund’s primary mandate is to provide growth capital to European companies that have moved past the initial research phase and are currently in the commercialisation stage. By targeting entities that are developing sophisticated medical devices, diagnostics, and digital health infrastructure, the fund seeks to improve the efficiency and efficacy of healthcare delivery across the continent.
For the British Business Bank, this investment is not merely a financial transaction but a policy-driven mechanism. The bank acts as a catalyst, deploying capital into high-quality international funds to ensure that the UK’s “high-potential” startups remain competitive on the global stage. This infusion of capital ensures that companies specializing in life-altering medical technology have the necessary liquidity to navigate the “valley of death”—the precarious period between initial clinical validation and widespread market adoption.
A Chronology of Collaboration and Investment
The relationship between the British Business Bank and EQT Life Sciences is rooted in a history of successful co-investments, establishing a track record of mutual trust and strategic alignment.
- 2023: The partnership gained significant momentum when the British Business Bank participated in the $42 million Series D financing round for Phagenesis, a Manchester-based medical device company specializing in treatments for dysphagia.
- 2024: EQT Life Sciences officially launched the EQT Health Economics 3 Fund, setting the stage for a new era of investment in the European medtech landscape.
- October 2025: The fund received a major vote of confidence from the Dutch promotional bank, Invest-NL, which contributed €15 million to the vehicle, further diversifying the fund’s institutional backing.
- September 2025: The British Business Bank reinforced its commitment to EQT’s portfolio by participating in Cyted Health’s $44 million Series B funding round. Cyted Health, a UK-based company focused on non-invasive diagnostics for gastrointestinal diseases, serves as a prime example of the type of high-growth entity that this partnership aims to nurture.
- Mid-2026: The current €25 million commitment from the British Business Bank represents the latest milestone in this ongoing collaboration, signaling a long-term commitment to the UK’s life sciences ecosystem.
Supporting Data: The EQT Life Sciences Footprint
EQT Life Sciences has cemented its reputation as a premier investor in the European health sector. With a portfolio that includes over 150 companies and more than €3.7 billion raised across 13 private funds, the firm provides more than just capital; it provides the operational expertise required to scale complex medical enterprises.
The fund’s scope is broad, encompassing:
- Medical Devices: Development of surgical tools, implantables, and monitoring equipment.
- Health Tech: Digital platforms that streamline patient management and diagnostic workflows.
- Diagnostics: Breakthrough technologies that facilitate earlier detection of chronic and acute conditions.
Recent notable activity by EQT includes backing Galway-based Neurent Medical, which specializes in innovative treatments for chronic rhinitis, and the Dutch insulin pump developer ViCentra, which recently secured significant funding to facilitate its expansion into the highly competitive US market. These investments demonstrate EQT’s ability to identify companies with the potential for international scalability, a key requirement for the British Business Bank’s investment criteria.
Official Responses and Strategic Rationale
The investment has been met with optimism from both the public and private sectors, with stakeholders emphasizing the necessity of specialized capital in the life sciences domain.
Christine Hockley, Managing Director and Head of Commercial Equity Funds at the British Business Bank, underscored the importance of the UK’s industrial strategy in guiding these decisions. “The UK is home to a world-class life sciences sector, but scaling companies in the sector requires specialist investors,” Hockley stated. “By investing in high-quality international funds, we encourage greater investment to flow back into the UK and ensure UK companies benefit from the capital and expertise of leading investors.”
This sentiment was echoed by Drew Burdon, a partner at EQT Life Sciences. Burdon highlighted the evolution of the relationship between the two organizations, noting that the bank’s history of co-investing in UK-based firms provided a solid foundation for the current commitment. “Over recent years, we have built an excellent relationship with the bank through co-investments in leading UK health tech companies,” Burdon noted. “The bank’s investment will further contribute to our commitment to tap into the attractive UK health tech ecosystem and grow strong companies together.”
Implications for the UK Life Sciences Sector
The implications of this investment are manifold, touching upon industrial strategy, job creation, and the advancement of healthcare delivery.
Alignment with the UK Industrial Strategy
The UK government has identified life sciences as one of the eight core pillars of its national Industrial Strategy. By aligning the British Business Bank’s investment portfolio with this strategy, the government is signaling that it views medtech not just as a health imperative, but as a critical economic engine. As the UK looks to post-Brexit growth, the ability to retain and scale home-grown innovation is paramount.
Bridging the Funding Gap
One of the primary challenges for UK medtech startups has been the "scale-up gap." While the UK has a high volume of early-stage research and spin-outs, many companies struggle to find the significant, late-stage funding required to launch global commercial operations. The partnership with EQT, an international firm with deep connections in European and US markets, provides a bridge for UK companies to access wider, deeper pools of capital.
Enhancing Patient Outcomes
Ultimately, the success of this investment will be measured in the clinic. By supporting companies like Phagenesis and Cyted Health, the EQT HE3 fund is accelerating the delivery of technologies that can reduce the burden on public healthcare systems, such as the NHS. Innovations that enable earlier diagnosis or more effective rehabilitation not only improve patient quality of life but also offer long-term cost savings to healthcare providers.
A Beacon for International Investment
The involvement of the British Business Bank acts as a "seal of approval," which often serves to de-risk investments for private institutional investors, such as pension funds and sovereign wealth funds. By committing €25 million, the bank is creating a multiplier effect, encouraging other private players to look toward the UK as a primary destination for life sciences investment.
Conclusion
The €25 million commitment from the British Business Bank to the EQT Health Economics 3 Fund is a strategic pivot that reflects the changing needs of the modern medtech landscape. As the sector moves toward a model defined by digital integration and highly specialized clinical outcomes, the requirement for sophisticated, growth-oriented capital becomes more acute.
Through this collaboration, the UK is effectively leveraging the expertise of a European heavyweight to ensure that its domestic startups are not only surviving but thriving. As the EQT HE3 fund continues to deploy capital, the ripple effects of this investment are expected to bolster the UK’s R&D capabilities, foster the growth of high-value job opportunities, and—most importantly—bring the next generation of medical technologies to the patients who need them most.
About the Author
